

# AGENDA FOR RFH MASTERCLASS 2026

## “NET Academy”



### Thursday 18<sup>th</sup> June

14: 00 – 15: 00: Registration - Light meal

15:00 – 15:10: Welcome - Introduction

#### **15:10 - 17:00 : SESSION A – DIAGNOSTICS IN ADVANCED NENs**

1. “Tips and Tricks” in GEP-NEN clinical assessment 10’
2. Pathology
  - a. The optimal GEP-NEN histopathology report 15’
  - b. The optimal thoracic NEN histopathology report 10’
  - c. Tissue biomarkers for differential diagnosis & Predictive prognostic tissue biomarkers 15’
3. Serum and urine NET biomarkers: where we stand in 2026? 15’
4. Imaging biomarkers
  - a. Tumour Growth Rate (TGR) 10’
  - b. The complementary role of FDG PET (NETPET score, discordant volume, metabolic volume etc) 15’
5. Optimal diagnostic algorithm – Histopathology Quiz - Interactive cases – Q&As 20’

**17:00 – 17:30 Tea / Coffee break / Networking**

### **17:30 – 18:15 SESSION B: SYMPTOMS' CONTROL**

1. NET emergencies (Carcinoid Crisis, Pheochromocytoma crisis, Cushing's crisis, Vipoma crisis) 15'
2. Optimal use of SSAs for refractory syndromes 15'

DISCUSSION - Q&A: 15'

### **18:15 – 18:55 SESSION C: NET "SPECIAL TOPICS"**

- How we can incorporate advances in Diagnostic and Therapeutic endoscopy into the management of GEP-NENs 15' + 5' discussion
- Non-surgical management of Carcinoid Heart Disease 15' + 5' discussion

### **18:55 – 19:00: CONCLUSIONS OF DAY 1**

### **20: 30: MASTERCLASS DINNER**

## **Friday 19<sup>th</sup> June**

### **08:45 – 10:15 SESSION D: SURGICAL DILEMMAS & ADVANCES IN NENs**

- PNETs: local vs radical resection 15'
- Downstaging strategies vs primary resection for locally advanced pNET disease 15'
- Locoregional treatments vs resection for NET hepatic metastases 15'
- Minimally invasive robotic surgical approaches combined with multi-modal small bowel assessment for small bowel NET 15'
- Surgical Considerations for bronchial NENs. 15'

DISCUSSION – Q&A : 15'

### **10:15 -11:00 SECTION E: TRANSPLANTATION IN GEP-NETs**

1. The possibility of small bowel transplantation in midgut NET 15'
2. The reality of liver transplantation for NET 15'

DISCUSSION – Q&A : 15'

### **11:00 – 11:30 Coffee-Tea break / Networking**

## **11:30 – 13:00 : SESSION F: ESTABLISHED TREATMENTS FOR ADVANCED NENs**

1. Molecular targeted agents: emerging data for everolimus and sunitinib for GEP NEN, Bronchial NEN, paraganglioma/phaeochromocytoma 15'
2. Systemic chemotherapy – “the old / good friend”: Choosing the appropriate patient, timing and regimen
  - a. *For GEP-NEN 15'*
  - b. *For bronchial NEN 10'*
3. Treatment with Lu-177 Radiolabelled peptides : “the game-changer”
  - a. *Appropriate position in treatment algorithms – impact on symptoms and quality of life (NETTER-2, COMPETE, OCCURANDOM, mentioning of NETTER-3 and COMPOSE) 15'*
  - b. *Precautions in challenging scenarios 15'*

DISCUSSION (FOR 1, 2 and 3) & Q&A: 20'

**13:00 – 14:00: Lunch break**

**14:00 – 16:00: TWO PARALLEL SESSIONS TO SESSION G & H:**

- a) **NET dietetics – NET Nursing**
- b) **NET BASIC RESEARCH, UK FORUM**

## **14:00 – 15:00 SESSION G: EMERGING TREATMENTS**

1. The future of radiolabelled treatments 15'
2. New TKIs 15'
3. Immunotherapy and new molecules 15'

DISCUSSION – Q&A: 15'

## **15:00 – 16:00 SESSION H: NENs IN CHALLENGING POPULATIONS**

- In pregnancy 15'
- In children / adolescents 15'
- In elderly 15'

DISCUSSION – Q&A : 15'

**16:00 – 16:30: Tea / Coffee Break / Networking**

## **16: 30 – 17:25 SESSION I: Live MDT**

*(Short cases, that need fundamental decisions, will be presented: we will mimic a “real-life” MDT)*

Panellists: Oncologist, Gastroenterologist, Endocrinologist, HPB Surgeon, Colorectal Surgeon, Radiologist, NM Physician, Histopathologist, Clinical Nurse Specialist

**17: 25 – 17:30: CONCLUSIONS**

